Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - trandolapril, quantity: 4 mg; verapamil hydrochloride, quantity: 240 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; povidone; hypromellose; sodium stearylfumarate; microcrystalline cellulose; sodium alginate; magnesium stearate; hyprolose; macrogol 400; macrogol 6000; purified talc; colloidal anhydrous silica; titanium dioxide; iron oxide red; iron oxide yellow; iron oxide black; docusate sodium - tarka is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - trandolapril, quantity: 2 mg; verapamil hydrochloride, quantity: 180 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; povidone; hypromellose; sodium stearylfumarate; microcrystalline cellulose; sodium alginate; magnesium stearate; hyprolose; macrogol 400; macrogol 6000; purified talc; colloidal anhydrous silica; titanium dioxide; iron oxide red; iron oxide yellow; iron oxide black; docusate sodium - tarka is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

United States - English - NLM (National Library of Medicine)

abbvie inc. - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o), verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - trandolapril 2 mg - tarka is indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration ). in using tarka, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see warnings - neutropenia/agranulocytosis ). tarka is contraindicated in patients who are hypersensitive to any ace inhibitor or verapamil. because of the verapamil component, tarka is contraindicated in: - severe left ventricular dysfunction (see warnings ). - hypotension (systolic pressure less than 90 mmhg) or cardiogenic shock. - sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). - second- or third-degree av block (except in patients with a functioning artificial ventricular pacem

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - trandolapril (unii: 1t0n3g9crc) (trandolapril - unii:1t0n3g9crc), verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - trandolapril 2 mg - tarka is indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration). in using tarka, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see warnings -neutropenia/agranulocytosis ). tarka is contraindicated in patients who are hypersensitive to any ace inhibitor or verapamil. because of the verapamil component, tarka is contraindicated in: - severe left ventricular dysfunction (see warnings ). - hypotension (systolic pressure less than 90 mmhg) or cardiogenic shock. - sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). - second- or third-degree av block (except in patients with a functioning artificial ventricular pacemak

Canada - English - Health Canada

abbott laboratories, limited - verapamil hydrochloride; trandolapril - tablet (extended-release) - 240mg; 1mg - verapamil hydrochloride 240mg; trandolapril 1mg - miscellaneous calcium-channel blocking agents

Canada - English - Health Canada

bgp pharma ulc - verapamil hydrochloride; trandolapril - tablet (extended-release) - 240mg; 2mg - verapamil hydrochloride 240mg; trandolapril 2mg - miscellaneous calcium-channel blocking agents

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd - trandolapril; verapamil hydrochloride -

Canada - English - Health Canada

bgp pharma ulc - trandolapril; verapamil hydrochloride - tablet (extended-release) - 4mg; 240mg - trandolapril 4mg; verapamil hydrochloride 240mg - miscellaneous calcium-channel blocking agents

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

abbvie deutschland gmbh & co. kg - trandolapril, verapamil (verapamil hydrochloride) - tablets modified-release film-coated - 4mg+ 240mg

Canada - English - Health Canada

abbott laboratories, limited - verapamil hydrochloride; trandolapril - tablet (extended-release) - 180mg; 2mg - verapamil hydrochloride 180mg; trandolapril 2mg - miscellaneous calcium-channel blocking agents